An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Status:
Recruiting
Trial end date:
2022-10-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in
participants with moderately to severely active ulcerative colitis (UC) who have had an
inadequate response to, loss of response, or intolerant to conventional or biologic therapy
for UC.